Abstract:Membranoproliferative glomerulonephritis (MPGN) is a renal pathological type characterized by the proliferation of mesangial cells and the insertion of mesangial matrix along endothelial cells and capillary basement membranes, forming a “double track sign”. The deposition of immunoglobulins (including immune complexes, monoclonal immunoglobulins, etc.) is one of its damage mechanisms. The main clinical manifestations of this disease are proteinuria (mostly a large amount of proteinuria), hypertension, renal hematuria, and impaired renal function, often accompanied by hypocomplementaemia, with poor prognosis. The efficacy of existing diagnostic and treatment plans for this disease is still uncertain. Rituximab is a specific human mouse chimeric monoclonal antibody against the B-cell surface antigen CD20. In recent years, some domestic and foreign scholars have applied rituximab to immunoglobulin mediated MPGN. Therefore, this article summarizes this in order to provide reference for the clinical treatment of immunoglobulin mediated MPGN.